ES2156932T3 - Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas. - Google Patents

Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.

Info

Publication number
ES2156932T3
ES2156932T3 ES95903221T ES95903221T ES2156932T3 ES 2156932 T3 ES2156932 T3 ES 2156932T3 ES 95903221 T ES95903221 T ES 95903221T ES 95903221 T ES95903221 T ES 95903221T ES 2156932 T3 ES2156932 T3 ES 2156932T3
Authority
ES
Spain
Prior art keywords
microparticles
antigen
biodegradable
potentiation
immunological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903221T
Other languages
English (en)
Inventor
Bruno Gander
Giampietro Corradin
Ying Men
Claudio Thomasin
Hans Peter Merkle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RMF Dictagene SA
Original Assignee
RMF Dictagene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RMF Dictagene SA filed Critical RMF Dictagene SA
Application granted granted Critical
Publication of ES2156932T3 publication Critical patent/ES2156932T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN PROCESO PARA LA POTENCIACION DE RESPUESTA INMUNOLOGICA EN ANTIGENOS SINTETICOS O DE INGENIERIA GENETICA DISPONIENDO DE BAJA CAPACIDAD INMUNOLOGICA. EL ANTIGENO SE ENCUENTRA EMBEBIDO DENTRO DE PARTICULAS BIODEGRADABLES, ESTANDO DISPERSAS ESTAS MICROPARTICULAS CARGADAS CON ANTIGENO EN UN MEDIO BIODEGRADABLE QUE SE DESENCADENA CUANDO ES ADMINISTRADO DE FORMA PARENTERAL EN UN ANTICUERPO POTENCIADO, CON RESPUESTA T{SUB,H} LINFOCITO Y RESPUESTA T{SUB,C} - LINFOCITO, EN COMPARACION CON UNA SOLUCION DE ANTIGENO ACUOSA. LA EXTENSION DE LA POTENCIACION INMUNOLOGICA ES AL MENOS COMPARABLE CON LA OBTENIDA POR MEDIO DE COMPOSICIONES IFA. LOS EPITOPES LINEALES B - T{SUB,T} - CELULA, EPITOPES LINEALES T{SUB,C} - CELULA, DIMEROS Y MULTIMEROS DE TALES EPITOPES, ASI COMO SUS MEZCLAS SON UTILIZADOS COMO ANTIGENOS DE BAJA CAPACIDAD INMUNOLOGICA. LAS MICROPARTICULAS SE BASAN EN BIOPOLIMEROS BIODEGRADABLES TALES COMO POLIESTER, POLIANHIDRIDO, POLIORTOESTER. MEDIANTE MEZCLADO DE MICROPARTICULAS CONDIFERENTE CAPACIDAD DE HUMECTACION, CAPACIDAD DE HINCHAMIENTO, LIBERACION Y TIEMPO DE BIODEGRADACION, SE CONSIGUE LA POTENCIACION MAS INTENSA EN DISPOSICION INMUNOLOGICA MAS LARGA. ESTE PROCESO ES UTILIZABLE PARA LA INMUNIZACION DE SERES HUMANOS Y ANIMALES CONTRA ENFERMEDADES ORIGINADAS PRO VIRUS, BACTERIAS, PROTOZOOS O CELULAS TUMORALES.
ES95903221T 1993-12-23 1994-12-23 Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas. Expired - Lifetime ES2156932T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH384993 1993-12-23

Publications (1)

Publication Number Publication Date
ES2156932T3 true ES2156932T3 (es) 2001-08-01

Family

ID=4264801

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903221T Expired - Lifetime ES2156932T3 (es) 1993-12-23 1994-12-23 Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.

Country Status (12)

Country Link
US (1) US6596278B2 (es)
EP (1) EP0686030B1 (es)
JP (1) JPH08507088A (es)
KR (1) KR100372375B1 (es)
CN (1) CN1120809A (es)
AT (1) ATE199316T1 (es)
AU (1) AU1217395A (es)
CA (1) CA2156718A1 (es)
DE (1) DE59409668D1 (es)
DK (1) DK0686030T3 (es)
ES (1) ES2156932T3 (es)
WO (1) WO1995017167A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
EP2286831A1 (en) * 1997-07-10 2011-02-23 Mannkind Corporation A method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6548302B1 (en) 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
JP4601823B2 (ja) 1998-09-01 2010-12-22 メリオン リサーチ スリー リミテッド 経口ワクチン組成物
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2007050242A1 (en) * 2005-10-24 2007-05-03 Staval Pharma, Ltd. Method for treating/controlling/killing fungi and bacteria
PT2114993E (pt) * 2007-01-15 2012-11-28 Glaxosmithkline Biolog Sa Vacina
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2011153532A1 (en) * 2010-06-04 2011-12-08 Flow Pharma Inc. Peptide particle formulation
CN102901814B (zh) * 2012-07-12 2014-11-26 浙江大学 莠去津分子印迹金标试纸条及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5762965A (en) * 1984-03-16 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
ES2085465T3 (es) 1989-11-13 1996-06-01 Abraham J Domb Lipoesferas para la administracion controlada de sustancias.
AU8303691A (en) * 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
EP0678034B1 (en) * 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
PT991403E (pt) 1997-01-30 2003-08-29 Chiron Corp Uso de microparticulas com antigenio adsorvido para estimular respostas imunes
EP1009386B1 (en) 1997-08-29 2005-08-31 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
ES2175668T3 (es) 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
JP4526708B2 (ja) 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤

Also Published As

Publication number Publication date
AU1217395A (en) 1995-07-10
US20020041879A1 (en) 2002-04-11
DK0686030T3 (da) 2001-06-25
KR100372375B1 (ko) 2003-04-21
KR960700692A (ko) 1996-02-24
CA2156718A1 (en) 1995-06-29
ATE199316T1 (de) 2001-03-15
EP0686030A1 (de) 1995-12-13
JPH08507088A (ja) 1996-07-30
DE59409668D1 (de) 2001-04-05
US6596278B2 (en) 2003-07-22
WO1995017167A1 (de) 1995-06-29
CN1120809A (zh) 1996-04-17
EP0686030B1 (de) 2001-02-28

Similar Documents

Publication Publication Date Title
ES2156932T3 (es) Microparticulas cargadas con antigeno y preparados farmaceuticos que contienen estas microparticulas.
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
Stacey et al. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
DK0678034T3 (da) Induktion af cytotoksiske T-lymfocytreaktioner
DE69810459D1 (de) Reagenzien zur impfung, die eine cd8 t-zell-immunantwort erzeugen
FI933328A0 (fi) Antigen producerande protein
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
DE69637481D1 (de) Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
ECSP055551A (es) Composiciones de vacunas que contienen arreglos de antígeno amiloide beta 1-6
BR0010823A (pt) Adjuvante de estabilidade, biocompatibilidade otimizada (sba) para realçar a resposta imune humoral e celular
CA2272338A1 (en) Immunization of infants
IL106968A0 (en) Potentiation of immunogenic response
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
CA2086097A1 (en) Adjuvants and vaccines
EP2057999A3 (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
CA2137638A1 (en) Anti Gangliosides Monoclonal Antibodies and Their Use in the Specific Active Immunotherapy of Malignant Tumors
CA2137363A1 (en) Use of Zona Pellucida Glycoproteins for Immunocontraception
JPH01500663A (ja) 動物の生殖機能の調節
CA2128247A1 (en) Vaccines based on streptokinase
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Lovgren Construction and potential of the iscom as immunogen.
YouNG-RoDENCHUK et al. Differences in the sensitivity of tumor cells and normal lymphocytes toward lysis by alloantibodies and guinea pig or rabbit complement
Edgington Immune responses and liver disease, perhaps. But what about target organ defenses?
Fedorovskaya et al. Immune response of the body of donors to pyocyaneus antigen formerly hyperimmunized with staphylococcal anatoxine.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686030

Country of ref document: ES